RxDoctor Payments Data

Richard Ross, MD

Family Medicine · Santa Monica, CANPI 1144274911

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 40 payments — averaging $32.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$335
  • Novo Nordisk$209
  • Lilly USA, LLC$161
  • Gilead$124
  • Johnson & Johnson$115
  • Teva Pharmaceuticals USA, Inc.$104
  • plus $261 from 6 others

What the payments were for

  • Food & beverage$1,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$54,552
Medicare patients
100
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$28,957
EliquisApixaban21$25,684
TrulicityDulaglutide22$19,132
Atorvastatin Calcium209$2,630
SynthroidLevothyroxine Sodium21$2,211
Humalog Mix 50-50 KwikpenInsulin Lispro Protamin/Lispro15$2,090
Wixela InhubFluticasone Propion/Salmeterol12$1,675
Tamsulosin Hcl79$1,415
Rosuvastatin Calcium51$1,189
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril44$1,141
Amlodipine Besylate106$788
Metformin Hcl75$731
ValacyclovirValacyclovir Hcl14$686
Levothyroxine Sodium52$648
Metoprolol Succinate36$538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$209$28,95731 claims
PfizerEliquis$78$25,68421 claims
Lilly USA, LLCTrulicity$161$19,13222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →